Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The <i>Streptococcus mutans</i> collagen-binding protein Cnm enhances early biofilm formation with <i>Candida albicans</i>.

Applied and environmental microbiology·2026
Same author

Acid ceramidase inhibition enhances BCL-2 targeting in venetoclax-resistant acute myeloid leukemia.

Blood neoplasia·2026
Same author

Pharmacological blockade of rho kinase enhances venetoclax responses in translational models of acute myeloid leukemia.

Haematologica·2026
Same author

Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.

Blood neoplasia·2026
Same author

Understanding the benefits of art therapy for cancer-related pain: a call for action.

Annals of medicine·2026
Same author

Trends in Utilization and Costs Following a Hepatitis C Elimination Initiative.

JAMA network open·2026

Related Experiment Video

Updated: Jun 10, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

A non-coding cationic lipid DNA complex produces lasting anti-leukemic effects.

Nikki Keasey1, Zachary Herse, Stella Chang

  • 1Penn State College of Medicine, Hershey, PA, USA.

Cancer Biology & Therapy
|July 22, 2010
PubMed
Summary

Cationic lipid DNA complex (CLDC) demonstrates potent anti-leukemic effects in mouse models by inhibiting tumor growth and extending survival. This immunostimulatory preparation induces interferon-gamma (IFNγ), suggesting a lasting immune response against leukemia.

More Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Related Experiment Videos

Last Updated: Jun 10, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Cationic lipid DNA complex (CLDC) is an immunostimulatory agent with demonstrated anti-leukemic properties.
  • CLDC has shown efficacy in preclinical models of BCR-ABL(+) myelogenous leukemia and myelomonocytic leukemia.

Purpose of the Study:

  • To evaluate the anti-leukemic effects of CLDC in murine models.
  • To investigate the immune response, including cytokine induction and adaptive immunity, following CLDC treatment.
  • To determine the impact of dosing and administration route on CLDC efficacy.

Main Methods:

  • Treatment of C3H/HeJ and BALB/c mice with CLDC following leukemic challenge.
  • Assessment of tumor growth inhibition, survival rates, and cytokine induction (IFNγ).
  • Evaluation of tachyphylaxis and adaptive immune responses to secondary leukemic challenge.

Main Results:

  • CLDC treatment inhibited leukemia tumor cell growth in vivo and extended survival, sometimes leading to tumor eradication.
  • Intravenous CLDC administration induced a more rapid and robust interferon-gamma (IFNγ) response compared to subcutaneous administration.
  • Repeated CLDC dosing led to tachyphylaxis, with optimal survival benefits observed at intermediate doses. Animals treated successfully showed a survival advantage against secondary leukemic challenge.

Conclusions:

  • CLDC is an effective therapeutic agent against experimental leukemias.
  • The anti-leukemic effects of CLDC are mediated by the induction of cytokines like IFNγ and the stimulation of a lasting T-helper 1 (TH1) immune response.
  • Dose optimization and administration route are critical for maximizing the therapeutic benefits of CLDC.